Abstract 233: Preclinical development of EIK1005, a potent and selective inhibitor of Werner helicase.
Fernando Rodriguez Perez(Therapeutics Clinical Research), Marcus P. Kelly(Io Therapeutics (United States)), Huntly M. Morrison, Brenda B. Smith(Therapeutics Clinical Research), Melissa Dumble(Rapt Therapeutics (United States)), Ali Tabatabaei, Danny Murnock, Rafael G. Miranda(University of Oregon), Stephen Jones(Io Therapeutics (United States)), Juanita Ezemba(Io Therapeutics (United States)), Jose Ortega(Therapeutics Clinical Research), Taylor Heuer(Io Therapeutics (United States)), Tamer Ahmed(Io Therapeutics (United States)), Stephen E. Basham(Therapeutics Clinical Research)
Cited by 0
Related Papers
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
|Nature Communications|2019|213
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
|Clinical Cancer Research|2014|111
Discovery of Potent and Selective RSK Inhibitors as Biological Probes
|Journal of Medicinal Chemistry|2015|84
Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers
|Molecular Cancer Research|2014|80